Viralytics - Termination of coverage
Edison Investment Research is terminating coverage on Viralytics (VLA). Please note you should no longer rely on any previous research or estimates...
37 Views
Viralytics - Looking towards pivotal Cavatak combo studies
Viralytics continues to report impressive preliminary data for Cavatak in combination with immune checkpoint inhibitors (ICIs), whether...
112 Views
Cavatak/Yervoy combo enters the spotlight
Viralytics’ presentations at AACR highlighted an impressive 36% response rate when melanoma patients refractory to the best available PD1/L1...
79 Views
Cavatak combo data at AACR next month
Viralytics will present updates on three Phase Ib trials of Cavatak in combination with marketed immune checkpoint inhibitor (ICI) drugs at the...
64 Views
Cavatak data continue to impress
Viralytics’ Cavatak continues to impress, with a 100% disease control rate in 10 patients (seven objective responses) in combination with Keytruda...
37 Views
No more insights